Centers for Disease Control and Prevention, National Center for Injury Prevention and Control, Division of Overdose Prevention, 4770 Buford Hwy, Atlanta, GA 30341, USA.
Drug Alcohol Depend. 2022 Jun 1;235:109467. doi: 10.1016/j.drugalcdep.2022.109467. Epub 2022 Apr 16.
The majority of drug overdose deaths in the United States involve opioids, and synthetic opioid-involved overdose death rates are increasing. Naloxone is a key prevention strategy yet estimates of its administration are limited.
We analyzed 2019 data from 37 states and the District of Columbia in CDC's State Unintentional Drug Overdose Reporting System to estimate the percentage of decedents, by sociodemographic subgroup, who experienced a fatal opioid-involved overdose and had no evidence of naloxone administration.
A total of 77.3% of 33,084 opioid-involved overdose deaths had no evidence of naloxone administration. Statistically significant subgroup differences were observed for all sociodemographic groups examined except housing status. The highest percentages of decedents lacking evidence of naloxone administration were those with highest educational attainment (doctorate or professional degree, 87.0%), oldest (55-64 years, 83.4%; ≥65 years, 87.3%) and youngest ages (<15 years, 87.5%), and single marital status (84.5%). The lowest percentages of no evidence of naloxone administration were observed for non-Hispanic American Indian/Alaskan Native persons (66.2%) and those ages 15-24 years (70.8%).
More than three-quarters of opioid-involved overdose deaths had no evidence of naloxone administration, underscoring the need to ensure sufficient naloxone access and capacity for utilization. While fatal overdose data cannot fully characterize sociodemographic disparities in naloxone administration, naloxone education and access efforts can be informed by apparent inequities. Public health partners can assist persons who use drugs (PWUD) by maintaining naloxone supply and amplifying messages about the high risk of using drugs alone among PWUD and their social networks.
美国大多数药物过量死亡涉及阿片类药物,且合成阿片类药物相关药物过量死亡人数正在增加。纳洛酮是一种关键的预防策略,但对其使用的估计是有限的。
我们分析了 2019 年疾病预防控制中心国家非故意药物过量报告系统中来自 37 个州和哥伦比亚特区的数据,以估计按社会人口统计学亚组划分的、经历致命阿片类药物相关药物过量且没有纳洛酮给药证据的死者比例。
在 33084 例阿片类药物相关药物过量死亡中,共有 77.3%的死者没有纳洛酮给药证据。除住房状况外,所有检查的社会人口统计学亚组均观察到统计学显著的亚组差异。缺乏纳洛酮给药证据的死者比例最高的是受教育程度最高的人群(博士或专业学位,87.0%)、年龄最大的人群(55-64 岁,83.4%;≥65 岁,87.3%)和年龄最小的人群(<15 岁,87.5%)以及单身婚姻状况(84.5%)。缺乏纳洛酮给药证据的比例最低的是未报告的非西班牙裔美洲印第安人/阿拉斯加原住民(66.2%)和 15-24 岁年龄组(70.8%)。
超过四分之三的阿片类药物相关药物过量死亡没有纳洛酮给药的证据,这突显了确保有足够的纳洛酮获得途径和使用能力的必要性。虽然致命药物过量数据不能完全描述纳洛酮给药方面的社会人口统计学差异,但纳洛酮教育和获取工作可以根据明显的不平等情况得到启发。公共卫生合作伙伴可以通过维持纳洛酮供应并放大关于独自使用药物的高危信息,来帮助药物使用者及其社交网络。